Results 121 to 130 of about 252,117 (230)

Life or cell death: identifying c-Myc regulated genes in two distinct tissues [PDF]

The c-myc oncogene is over-expressed or deregulated in many human cancers. c-myc encodes a transcription factor, the oncoprotein c-Myc (Myc), which acts as a master regulator of genes involved in such diverse cellular processes as replication and growth,
Robson, Samuel Charles
core  

Gasdermin‐Mediated Pyroptosis: Novel Strategies Against Colorectal Cancer

Cancer Science, EarlyView.
Pyroptosis is a double‐edged sword in colorectal cancer (CRC): chronic low‐grade pyroptosis promotes tumor progression, whereas acute induction of pyroptosis in cancer cells triggers antitumor immunity and enhances therapeutic response. Targeting gasdermin‐mediated pyroptosis represents a promising strategy for CRC treatment.
Kaibo Guo, Yuqian Feng, Jiamin Lu, Nuerbiye Abudurexiti, Xinlei Zhou, Mengfan Wei, Song Zheng   +6 more
wiley   +1 more source

NF1 and SPRED1/2 cooperate through RAS-MAPK-independent functions. [PDF]

Proc Natl Acad Sci U S A
Silva JM, Canche L, Cheng A, Young LC, McCormick F.   +4 more
europepmc   +1 more source

Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr‐Mutant Lung Cancer Mouse Model

Cancer Science, EarlyView.
Using an immunocompetent mouse model of Egfr Ex19del‐driven lung cancer, we found that osimertinib‐resistant tumors acquired Egfr V804F, the murine counterpart of human EGFR V802F. Afatinib, but not osimertinib, suppressed phosphorylation of EGFR and overcame V804F‐mediated resistance, providing a preclinical rationale for biomarker‐guided therapy ...
Takaaki Tanaka, Masato Fujitani, Masataka Taoka, Iwao Shimomura, Sachi Okawa, Shunta Mori, Tadahiro Kuribayashi, Jun Nishimura, Tomoka Nishimura, Ayako Morita, Naofumi Hara, Kiichiro Ninomiya, Go Makimoto, Hisao Higo, Kammei Rai, Eiki Ichihara, Shuta Tomida, Katsuyuki Hotta, Yosuke Togashi, Yoshinobu Maeda, Katsuyuki Kiura, Ryohei Katayama, Kadoaki Ohashi   +22 more
wiley   +1 more source

Vitamin D₃ and Dimethyl Fumarate Partially Restore Neurotrophic Signaling Without Altering Mitochondrial Integrity in the STZ-Induced Model of Sporadic AD. [PDF]

Int J Mol Sci
Piekarczyk N, Berezka P, Domkowicz K, Myślińska D, Kaczor JJ.   +4 more
europepmc   +1 more source

Influenza A viruses and PI3K signalling

, 2008
The influenza A virus non-structural (NS1) protein is multifunctional, and during virus-infection NS1 interacts with several factors in order to manipulate host-cell processes.
Hale, Benjamin G.
core  

Oncogenic BRAF and KRAS Promote Global DNA Hypomethylation Through a Directed Pathway That Upregulates TET3

Cancer Science, EarlyView.
Oncogenic BRAF and KRAS promote global DNA hypomethylation through a directed pathway that increases the levels of TET3, which helps drive tumorigenesis. ABSTRACT Aberrant epigenetic modification is one of the characteristics of the cancer genome.
Ichiro Onoyama, W. Rod Hardy, Shoichiro Takeishi, Lihua Julie Zhu, Yanglan Tan, Lloyd Hutchinson, Jianhong Ou, Leyuan Ma, Ching‐Man Virbasius, Masafumi Yasunaga, Keiichi I. Nakayama, Scott A. Shaffer, Michael R. Green   +12 more
wiley   +1 more source

Limonoid 7-Deacetoxy-7-oxogedunin (CG-1) Attenuates RANKL-Induced Osteoclastogenesis via Inhibiting PI3K/Akt-NFATc1 Axis. [PDF]

Cells
Koike A, Fujimori K.
europepmc   +1 more source

The N-terminal region of proto-dbl down regulates its transforming activity

, 1989
The dbl proto-oncogene can transform NIH3T3 cells when overexpressed, but its transforming activity is about 50 to 70 fold lower than that of the dbl oncogene. The dbl oncogene encodes a protein of 478 amino-acids while proto-dbl encodes a protein of 925
Ron, D, Aaronson, S, Eva, A, Eva, A., GRAZIANI, GRAZIA, Graziani, G   +5 more
core  

Targeting Cell Cycle Vulnerabilities in Cancers: Emerging Strategies for Therapeutic Development

Cancer Science, EarlyView.
Dysregulated cell cycle control often involves alternative compensatory pathways in cancers to maintain its robustness but provide unique targetable vulnerabilities. We overview recent insights on cancer‐specific vulnerabilities across the cell cycle and discuss how these can be used to develop new therapeutic strategies.
Nana Kamakura, Minji Jo, Motoko Takahashi, Toru Hirota   +3 more
wiley   +1 more source